Leona Kim-Schluger, MD
Dr. Kim-Schluger, whose clinical practice and research has shaped the treatment of patients with viral hepatitis, has been named Associate Director of the Recanati/Miller Transplantation Institute.
Dr. Kim-Schluger had left Mount Sinai several years ago to be closer to her school age children. She states coming back to Mount Sinai was a "no brainer". She missed the staff at the Recanati/Miller TransplantationInstitute, who are dedicated to patient care and advancing the treatmentof liver diseases. "Together with Dr. Sander Florman, MD, the Director of the Recanati/Miller Transplant Institute, our goal is to build a first-class transplant program that provides superior patient care and treatment."
There are a disproportionately high number of patients suffering from liver diseases in the communities surrounding Mount Sinai. Some are infected with the hepatitis C virus (HCV). Approximately 8,000 to 10,000 deaths annually are caused by HCV in the United States alone. The virus is a risk factor for liver cancer and is a leading cause for liver transplantation in the United States.
Dr. Kim-Schlugeris involved in clinical trials involving novel therapies that she hopesin the future will lead to a cure for hepatitis C. "The beauty of transplant is that the success depends upon not just a physician, but a team of individuals working together to achieve a common goal. Additionally, the gratification of saving lives is a profound experience."
Dr. Kim-Schluger has published numerous articles on viral hepatitis and transplantation in notable scientific journals such as the American Journal of Transplantation, Annals of Surgery, and Hepatology. She is the recipient of prestigious teaching awards and honors, including the Harry S. Altman Prize in Pediatrics and the 2009 Housestaff Teaching Award from Westchester Medical Center, New York Medical College.
"When a person is diagnosed with liver disease or in need of a transplant, I want them to think of coming to RMTI," she says.